Autophagy (macroautophagy) is a cellular degradation pathway essential for clearing misfolded proteins, damaged organelles, and toxic aggregates in Parkinson's disease. Enhancing autophagy represents a promising strategy to reduce alpha-synuclein burden and protect dopaminergic neurons[1].
Autophagy is a highly conserved cellular process that degrades and recycles cellular components. In neurodegenerative diseases, autophagy is frequently impaired, leading to accumulation of toxic protein aggregates. In Parkinson's disease, dysfunction in autophagic pathways contributes to the progressive loss of dopaminergic neurons in the substantia nigra. The mTOR (mammalian target of rapamycin) pathway plays a central role in regulating autophagy initiation, with mTOR activity typically being elevated in neurodegenerative conditions, suppressing autophagy and promoting aggregate accumulation[2].
The autophagy machinery involves multiple protein complexes that work in concert to form autophagosomes and deliver their contents to lysosomes for degradation[3]:
The ULK1 complex serves as the master initiator of autophagy, receiving upstream signals from nutrient sensors like mTOR and energy sensor AMPK. Under conditions of cellular stress or nutrient deprivation, ULK1 phosphorylates multiple downstream targets to initiate autophagosome nucleation. The Beclin 1-VPS34 complex is essential for the formation of the isolation membrane (phagophore) that expands to become the autophagosome. The ATG5-ATG12 conjugation system and LC3 lipidation are critical for membrane closure and cargo recognition[4].
Multiple points in the autophagy pathway can be targeted therapeutically[5]:
Macroautophagy is the primary form of autophagy relevant to neurodegeneration. It involves the formation of a double-membrane autophagosome that engulfs cytoplasmic components and fuses with lysosomes. This process is essential for the clearance of protein aggregates, damaged mitochondria (mitophagy), and other cellular debris. Studies in mouse models have demonstrated that loss of autophagy in neural cells leads to progressive neurodegeneration, confirming its critical role in neuronal survival[7][8].
In Parkinson's disease, macroautophagy is impaired at multiple stages, including autophagosome formation, cargo recognition, and lysosomal fusion. The accumulation of autophagic vacuoles in dopaminergic neurons of PD patients suggests a block in the later stages of autophagy, particularly at the fusion step with lysosomes. This defect leads to the buildup of undigested material and impaired clearance of alpha-synuclein aggregates[9].
Chaperone-mediated autophagy (CMA) is a selective form of autophagy that directly translocates cytosolic proteins containing a KFERQ motif across the lysosomal membrane through the LAMP-2A receptor[10]. Unlike macroautophagy, CMA does not require membrane formation and is highly selective for specific protein substrates.
In Parkinson's disease, CMA is particularly important for alpha-synuclein degradation. Mutant forms of alpha-synuclein that accumulate in PD have been shown to bind to LAMP-2A with high affinity, blocking CMA and leading to further accumulation of toxic species. This creates a vicious cycle where alpha-synuclein accumulation impairs its own degradation pathway. Enhancing CMA represents a targeted approach to specifically increase clearance of alpha-synuclein and other PD-relevant proteins[11][12].
Mitophagy is the selective autophagy of mitochondria, critical for maintaining mitochondrial quality control. In Parkinson's disease, mitophagy is particularly relevant due to the involvement of PINK1 and Parkin in this pathway. Under normal conditions, PINK1 accumulates on damaged mitochondria and recruits Parkin to ubiquitinate mitochondrial proteins, marking the mitochondrion for autophagic degradation[13].
In PD, mutations in PINK1 (PARK6) and PARK2 (Parkin) impair mitophagy, leading to accumulation of dysfunctional mitochondria that generate excessive reactive oxygen species (ROS) and trigger apoptosis. This mitochondrial dysfunction is a central feature of dopaminergic neuron loss in the substantia nigra. Enhancing mitophagy through pharmacological intervention could help restore mitochondrial homeostasis and protect neurons[14][15][16].
Multiple small molecules have been investigated for their ability to enhance autophagy in neurodegenerative disease models[17][18]:
| Compound | Target | Status | Clinical Evidence |
|---|---|---|---|
| Trehalose | mTOR-independent | Phase 2 | Reduces alpha-synuclein in PD models[19] |
| Rapamycin | mTOR | Phase 2 | Neuroprotective in MPTP models[20] |
| Erythropoietin | Multiple | Phase 2 | Neuroprotective, enhances autophagy |
| Lithium | IMPase/GSK-3β | Phase 1/2 | Reduces tau and alpha-synuclein[21] |
| Carbamazepine | Beclin 1 | Preclinical | Enhances autophagy in PD models |
| Latrunculin A | Actin | Preclinical | Promotes autophagosome-lysosome fusion |
Trehalose is a natural disaccharide that promotes autophagy through mTOR-independent pathways[22]. Its mechanism involves multiple pathways:
In PD models, trehalose has shown significant neuroprotective effects through enhanced clearance of alpha-synuclein and improved mitochondrial function. Studies in MPTP-treated mice demonstrated that trehalose administration protected dopaminergic neurons and improved motor function. The compound's ability to cross the blood-brain barrier and its favorable safety profile make it an attractive candidate for clinical development[19:1].
Rapamycin (sirolimus) is an FDA-approved immunosuppressant that inhibits mTORC1, thereby relieving mTOR-mediated suppression of autophagy[20:1]. While rapamycin has shown promise in preclinical models, its immunosuppressant effects and potential metabolic side effects limit its long-term use for neurodegenerative diseases.
Second-generation rapalogs (rapamycin analogs) such as CCI-779 (temsirolimus) and RAD001 (everolimus) offer improved pharmacokinetics and reduced immunosuppressive effects. These compounds have demonstrated neuroprotective effects in multiple neurodegenerative disease models. In PD models, rapamycin and analogs protect against dopaminergic neuron loss through enhanced mitophagy and reduced neuroinflammation.
Lithium has been used for decades to treat bipolar disorder and more recently has shown promise in neurodegenerative diseases. Its neuroprotective effects are mediated through multiple mechanisms, including:
In PD models, lithium has been shown to reduce alpha-synuclein aggregation and protect dopaminergic neurons. Importantly, the concentrations required for neuroprotection are lower than those used for mood stabilization, potentially allowing for safer long-term treatment[21:1][23].
Direct targeting of ATG proteins offers more specific modulation of autophagy[24]:
TFEB (Transcription Factor EB) is the master transcriptional regulator of lysosomal biogenesis and autophagy[6:1]. By activating TFEB, therapeutic agents can simultaneously increase:
TFEB overexpression in animal models of PD has shown remarkable neuroprotective effects. AAV-mediated TFEB delivery protected dopaminergic neurons and improved behavioral outcomes. Small molecule TFEB activators are in development, with compounds like genistein and trehalose showing partial TFEB activation. Gene therapy approaches using AAV-TFEB are in preclinical testing.
In PD, autophagy enhancement targets multiple pathological features[5:1]:
Multiple PD genes (LRRK2, GBA, SNCA, PINK1, PARK2) are directly involved in autophagy pathways, making autophagy modulation a broadly relevant therapeutic strategy.
Autophagy enhancers also show promise in AD:
In HD, polyglutamine aggregates are cleared through enhanced autophagy[23:1]:
| Compound | Trial Phase | Sponsor | Indication | NCT Number |
|---|---|---|---|---|
| Trehalose (Venglustat) | Phase 2 | Sanofi | Parkinson's disease | NCT02919839 |
| Rapamycin | Phase 2 | Various | PD with dementia | NCT03339492 |
| Lithium | Phase 1/2 | Various | ALS, PD | NCT02035995 |
| Erythropoietin | Phase 2 | Various | PD | NCT01976624 |
Several obstacles must be addressed for successful clinical development[24:1]:
Developing biomarkers to monitor autophagy modulation is essential:
The rationale for autophagy enhancement in neurodegeneration is compelling:
Autophagy enhancers may be combined with other approaches:
Last updated: 2026-03-28
Rubinsztein DC, et al. Autophagy and neurodegeneration. J Clin Invest. 2015. ↩︎
Mizushima N, et al. Autophagy in neurodegeneration. Nat Rev Neurol. 2018. ↩︎
Kuma A, et al. The formation of autophagy and its role in the clearance of protein aggregates. Autophagy. 2004. ↩︎
Ge P, et al. Beclin 1 and autophagy in neurodegeneration. Cell Mol Neurobiol. 2017. ↩︎
Schneider JL, et al. The role of autophagy in Parkinson's disease. Nat Rev Neurol. 2020. ↩︎ ↩︎
Decressac M, et al. TFEB overexpression rescues neurodegeneration in multiple models of Parkinson's disease. Nat Commun. 2013. ↩︎ ↩︎
Komatsu M, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006. ↩︎
Hara T, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006. ↩︎
Martinez-Vicente M, et al. Cargo recognition failure and long dysfunctional autophagy leads to neuronal accumulation of alpha-synuclein aggregates. Brain. 2010. ↩︎
Cuervo AM, et al. Chaperone-mediated autophagy: a novel autophagy process involved in protein quality control. Autophagy. 2004. ↩︎
Xilouri M, et al. Impact of chaperone-mediated autophagy in Parkinson's disease. J Parkinsons Dis. 2016. ↩︎
Martinez A, et al. Chaperone-mediated autophagy in neurodegenerative diseases. Nat Rev Neurol. 2008. ↩︎
Youle RJ, et al. Mitochondrial autophagy. Nat Rev Mol Cell Biol. 2015. ↩︎
Mittal S, et al. The PARK genes and their role in autophagy and mitophagy in Parkinson's disease. J Neural Transm. 2017. ↩︎
Williams A, et al. Relationship of PINK1 and parkin in mitophagy. Nat Rev Neurosci. 2019. ↩︎
Lin QF, et al. Mitochondrial quality control in Parkinson's disease and the role of PINK1/Parkin. Exp Neurol. 2019. ↩︎
Vande Haar C, et al. Inhibition of mTOR by rapamycin as a therapeutic strategy for neurodegenerative diseases. Nat Rev Drug Discov. 2009. ↩︎
Brito O, et al. mTOR signaling and autophagy in neurodegeneration. Neurobiol Dis. 2019. ↩︎
De Ciechi A, et al. Trehalose: a promising therapeutic strategy for Parkinson's disease. Neurobiol Dis. 2018. ↩︎ ↩︎
Malagelada C, et al. Rapamycin and rapamycin derivatives in neuroprotection. Autophagy. 2010. ↩︎ ↩︎
Bauer PO, et al. Lithium in neurodegeneration: more than a stabilizer. J Alzheimers Dis. 2010. ↩︎ ↩︎
Sarkar S, et al. Trehalose induces autophagy via mTOR-independent pathways. J Biol Chem. 2014. ↩︎
Imarisio S, et al. Lithium reduces toxicity in Huntington's disease models. Curr Alzheimer Res. 2009. ↩︎ ↩︎
Stepanenko A, et al. Age-related changes in autophagy in Parkinson's disease. Ageing Res Rev. 2015. ↩︎ ↩︎